slides · global inventory
Solution
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 8,880
Current window 5,941-5,970
Pages 296
Rows per page 30
Slide type
5,941-5,970 of 8,880
06
Uses a process diagram to illustrate the transition from cold to hot tumor states via viral infection.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
07
The central diagram shows a biological mechanism comparing 'Absence of Effector T Cells' (Platinum resistant) vs 'Presence of Effector T Cells' (Platinum sensitive).Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
23
The slide highlights a combination therapy approach involving oncolytic immunotherapy and adoptive cell therapy.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
27
The slide categorizes the platform's capabilities into therapeutic genes, immune modularity, and therapeutic antibodies, emphasizing non-GMO status and GLP tox readiness.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
38
The slide uses clinical study data (VIRO-15, NCT01443260) to support its claims.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
07
The slide uses a process flow diagram to illustrate the user journey and system architecture.HeartBeam | Investor Presentation Deck | 18 slides · HeartBeam
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
05
Includes a cartoon mascot at the bottom.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
09
Includes comparative bar charts and flow cytometry data.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
19
The slide uses a side-by-side comparison structure to explain two distinct but complementary technology platforms.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
33
Includes scientific diagrams of molecular pathways and efficacy data charts.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
43
The slide uses a process-flow layout to connect platform capabilities to specific product outputs.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
44
The slide uses a '3 Pillars' framework to explain the platform foundation, followed by a product-specific breakdown.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
45
Includes technical diagrams of the drug delivery mechanism and comparative survival data.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
47
Includes detailed scientific diagrams of the drug mechanism and clinical trial results.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
26
The slide uses a circular diagram to categorize 'Solutions' and 'Applications' in capital markets.Lazard | Investor Presentation Deck | 46 slides · Lazard
Pitch deck Investor relations Beat · Team1 hit
06
The slide uses a chromosome icon for the lead asset and a fast-forward icon for the pipeline strategy.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Problem1 hit
10
The slide uses a visual comparison between telomere targeting (left) and PD-1/PD-L1 checkpoint inhibition (right).MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
12
The chart shows tumor volume over time, highlighting the efficacy of the THIO + Atezo combination compared to controls.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pattern Hunter1 hit
22
The slide shows a biological mechanism of action (MOA) validation using a dot plot to show TIFs increase over 72 hours.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
15
The slide outlines a multi-step diagnostic process involving FIT analysis, automated extraction, qPCR, and AI/ML analysis.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
07
The slide outlines the technical workflow from sample collection (FIT tube and DNA stabilization tube) through analysis to the final patient report.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
13
The slide uses a process flow to demonstrate the technical workflow of the diagnostic test.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Solution1 hit
08
Uses a before-after-bridge style framing to contrast pain points with platform capabilities.MaxCyte | Investor Presentation Deck | 19 slides · MaxCyte
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
09
The slide highlights the transition from RUO to cGMP capabilities across the product line.MaxCyte | Investor Presentation Deck | 19 slides · MaxCyte
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
05
The slide uses a product photo to demonstrate the physical form factor of the sensor.Nemaura Medical | Investor Presentation Deck | 19 slides · Nemaura Medical
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
Nemaura Medical | Investor Presentation Deck | 19 slidesNemaura Medical | Investor Presentation Deck | 19 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
06
Uses a Venn diagram to illustrate the intersection of solving for resistance and selectivity.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
08
Uses a visual comparison framework to contrast traditional non-selective kinase inhibitors with the company's selective approach.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
09
The slide uses a list of icons to represent key clinical attributes of the drug candidate.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
14
The chart on the right uses a log scale for the y-axis to visualize selectivity indices.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Hypothesis Test1 hit